LIGAND PHARMACEUTICALS INC's ticker is LGND and the CUSIP is 53220K504. A total of 204 filers reported holding LIGAND PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.04 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,264,306 | +24.4% | 204,678 | +49.7% | 0.05% | +17.5% |
| Q2 2023 | $9,859,675 | -12.7% | 136,750 | -10.9% | 0.04% | -16.7% |
| Q1 2023 | $11,294,623 | +50.8% | 153,543 | +37.0% | 0.05% | +26.3% |
| Q4 2022 | $7,488,614 | +44.3% | 112,105 | +92.7% | 0.04% | -2.6% |
| Q2 2022 | $5,191,000 | +2157.0% | 58,178 | +3216.9% | 0.04% | +1200.0% |
| Q2 2021 | $230,000 | -32.9% | 1,754 | -22.1% | 0.00% | -50.0% |
| Q1 2021 | $343,000 | +7.9% | 2,251 | -29.7% | 0.01% | 0.0% |
| Q4 2020 | $318,000 | -30.3% | 3,202 | -33.1% | 0.01% | -40.0% |
| Q3 2020 | $456,000 | -26.7% | 4,789 | -19.7% | 0.01% | -64.3% |
| Q4 2019 | $622,000 | -18.1% | 5,967 | -21.7% | 0.03% | +64.7% |
| Q3 2019 | $759,000 | -19.0% | 7,622 | -7.2% | 0.02% | -26.1% |
| Q2 2019 | $937,000 | +154.6% | 8,209 | +512.6% | 0.02% | +64.3% |
| Q3 2018 | $368,000 | +441.2% | 1,340 | +168.0% | 0.01% | +180.0% |
| Q4 2017 | $68,000 | – | 500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| KNOTT DAVID M | 353,041 | $36,819,000 | 14.92% |
| CARDINAL CAPITAL MANAGEMENT LLC /CT | 919,994 | $95,946,000 | 2.93% |
| Elk Creek Partners, LLC | 236,862 | $24,702,000 | 2.84% |
| Conestoga Capital Advisors, LLC | 619,653 | $64,624,000 | 1.56% |
| WOODSTOCK CORP | 71,489 | $7,456,000 | 1.21% |
| Summit Creek Advisors LLC | 70,962 | $7,401,000 | 1.16% |
| FALCON POINT CAPITAL, LLC | 8,115 | $846,000 | 1.08% |
| RICE HALL JAMES & ASSOCIATES, LLC | 302,503 | $31,548,000 | 1.07% |
| Stephens Investment Management Group LLC | 508,100 | $52,990,000 | 1.00% |
| Tygh Capital Management, Inc. | 55,672 | $5,806,000 | 0.96% |